Loading data for CLYM — first visit, this takes a few seconds.
Climb Bio Inc. (CLYM)
NasdaqGM: CLYM
· Real-Time Price · USD
17.16
-0.68 (-3.81%)
At close: Aug 28, 2026, 8:00 PM
14.40
-1.15%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
Climb Bio Inc. (CLYM) Stock Price, Analysis & Data
-3.81% (1D)
No data available
| Bid | 9.05 |
| Market Cap | 836.85M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -57.62M |
| 0.08 | |
| -0.82 | |
| n/a | |
| -13.82 | |
| P/B (ttm) | 3.49 |
| P/S (ttm) | n/a |
| Earnings Date | Aug 14, 2025 |
| Ask | 16.06 |
| Volume | 86,603 |
| Avg. Volume (20D) | 1,337,695 |
| Open | 17.80 |
| Previous Close | 17.84 |
| Day's Range | 16.95 - 17.80 |
| 52-Week Range | 1.54 - 18.33 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CLYM
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; a...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 10, 2021
Employees 28
Stock Exchange NasdaqGM
Ticker Symbol CLYM
Website https://climbbio.com
Financial Performance
In 2025, Climb Bio's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -59.85M, a decrease of -19.01%.
Financial StatementsEarnings Surprise
Climb Bio has released their quarterly earnings on Aug 6, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.18 exceeds estimates by 0.03, with -38.46% YoY decline.
Climb Bio Inc. is scheduled to release its earnings on Aug 14, 2025, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2